Proudly celebrating 60 years in mental health
In 2018, we proudly mark the 60th year of Janssen’s continued dedication to the area of mental health. Our journey began in 1958, with Dr Paul Janssen’s discovery of a pioneering antipsychotic drug, haloperidol, challenging the tradition of institutionalisation. Since then, we have continued to reduce the burden, disability and devastation caused by mental health disorders, by understanding and producing treatments that address the most serious unmet medical needs.
We recognise that the importance of continuous treatment and non-adherence is a consistent feature of schizophrenia, which is why we consistently pursue the development of long-acting formulations of our most prominent antipsychotic treatments.
Over the last 60 years we have produced more than 20 medications and innovations1 – two of which, haloperidol and risperidone, are on the World Health Organization’s list of essential medicines2 – which have collectively helped to shape the care of neuropsychiatric diseases.
Mental health affects us all – one in four people in the world will be affected by mental health or mood disorders at some point in their lives3 – and we celebrate this legacy in the knowledge that we remain steadfast in our commitment to transforming and improving individual lives.
As well as providing life-changing treatments, we use our heritage and commitment in neuroscience to enhance patient care.
We also have one of the strongest pipelines in depression with seven compounds currently in development.